Search - tctmd.com

Displaying 381 - 400 of 808

Sort: Relevancy | Date

Presentation TCT 2013

Practical Applications and Future Projections for Bioabsorbable Vascular Scaffolds in Percutaneous Coronary Interventions

Presenter: D. Christopher Metzger

October 29, 2013

Presentation TCT 2013

How Do I Assess Causes of Stent Thrombosis or In-Stent Restenosis?

Presenter: Soo-Jin Kang

October 29, 2013

Presentation TCT 2013

You Want to Improve Outcomes in DES Patients? The Right Pharmacotherapy Is More Important Than the Right Stent!

Presenter: Gregg Stone

October 28, 2013

Presentation TCT 2013

Yes! With Current DES and Pharmacotherapy, SYNTAX Is Already Obsolete and the Majority of Patients with MVD Can Be Managed with PCI

Presenter: Dean Kereiakes

October 28, 2013

Presentation TCT 2013

Twelve Months or Longer Is Still the Right Recommendation!

Presenter: Laura Mauri

October 28, 2013

Presentation TCT 2013

Triple Therapy (DAPT Plus Chronic Oral Anticoagulation): Risks and Therapeutic Alternatives

Presenter: Eugenia Nikolsky

October 28, 2013

Presentation TCT 2013

The Promus Element Everolimus-Eluting Stent: Design Considerations and Clinical Trial Results (from PLATINUM to HOST-ASSURE)

Presenter: Hyo-Soo Kim

October 28, 2013

Presentation TCT 2013

Structural vs. Biologic DES Failure Modes: Experimental Insights

Presenter: Elazer Edelman

October 28, 2013

Presentation TCT 2013

Quantifying the Quality-of-Life Benefits of PCI in Stable Ischemic Heart Disease

Presenter: John Spertus

October 28, 2013

Presentation TCT 2013

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Presenter: Laura Mauri

October 28, 2013

Presentation TCT 2013

Not So Fast! Patient Oriented Outcomes Are Not So Different with New Technology: Most MVD Patients Benefit by CABG

Presenter: Vasim Farooq

October 28, 2013

Presentation TCT 2013

Longitudinal Stent Deformation and Strut Fracture: Common Causes of Restenosis and Stent Thrombosis?

Presenter: John Ormiston

October 28, 2013

Presentation TCT 2013

It Is Time to Scale Back to Three to Six Months!

Presenter: Fausto Feres

October 28, 2013

Presentation TCT 2013

Introduction of a New Definition of" Clinically Relevant" Myocardial Infarction: SCAI Consensus Document

Presenter: Issam Moussa

October 28, 2013

Presentation TCT 2013

Importance of Incomplete Revascularization after PCI: Anticipating RIVER-PCI

Presenter: Giora Weisz

October 28, 2013

Presentation TCT 2013

Drug-Eluting Balloons

Presenter: Jochen W?hrle

October 28, 2013

Presentation TCT 2013

Do I Really Need Bioresorbable Scaffolds in Germany?

Presenter: Bernhard Witzenbichler

October 28, 2013

Presentation TCT 2013

Design and Rationale of GLOBAL LEADERS

Presenter: Stephan Windecker

October 28, 2013

Presentation TCT 2013

Bioresorbable Vascular Scaffolds

Presenter: Robert-Jan van Geuns

October 28, 2013

Presentation TCT 2013

Yes! The European Union Has It Right

Presenter: Gilles Montalescot

October 28, 2013

Advertisement

Practical Applications and Future Projections for Bioabsorbable Vascular Scaffolds in Percutaneous Coronary Interventions

How Do I Assess Causes of Stent Thrombosis or In-Stent Restenosis?

You Want to Improve Outcomes in DES Patients? The Right Pharmacotherapy Is More Important Than the Right Stent!

Yes! With Current DES and Pharmacotherapy, SYNTAX Is Already Obsolete and the Majority of Patients with MVD Can Be Managed with PCI

Twelve Months or Longer Is Still the Right Recommendation!

Triple Therapy (DAPT Plus Chronic Oral Anticoagulation): Risks and Therapeutic Alternatives

The Promus Element Everolimus-Eluting Stent: Design Considerations and Clinical Trial Results (from PLATINUM to HOST-ASSURE)

Structural vs. Biologic DES Failure Modes: Experimental Insights

Quantifying the Quality-of-Life Benefits of PCI in Stable Ischemic Heart Disease

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Not So Fast! Patient Oriented Outcomes Are Not So Different with New Technology: Most MVD Patients Benefit by CABG

Longitudinal Stent Deformation and Strut Fracture: Common Causes of Restenosis and Stent Thrombosis?

It Is Time to Scale Back to Three to Six Months!

Introduction of a New Definition of" Clinically Relevant" Myocardial Infarction: SCAI Consensus Document

Importance of Incomplete Revascularization after PCI: Anticipating RIVER-PCI

Drug-Eluting Balloons

Do I Really Need Bioresorbable Scaffolds in Germany?

Design and Rationale of GLOBAL LEADERS

Bioresorbable Vascular Scaffolds

Yes! The European Union Has It Right

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content